Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands.
J Nucl Med. 2011 Jan;52(1):77-80. doi: 10.2967/jnumed.110.076711. Epub 2010 Dec 13.
18F-FDG PET is a sensitive, promising method for visualizing disease activity in rheumatoid arthritis. This study aimed to assess the association between changes in 18F-FDG joint uptake after 2 wk of infliximab treatment and clinical outcome.
Scans were obtained at the initiation of treatment and at 2 wk. Uptake in metacarpophalangeal and wrist joints was quantified using standardized uptake values.
Changes in mean standardized uptake value at 0-2 wk significantly correlated with the disease activity score (DAS) at 14 and 22 wk and contributed significantly to the prediction of DAS at these time points. No significant correlation was found between changes in acute-phase reactants at 0-2 wk and the DAS at later time points.
Early changes in 18F-FDG uptake in joints during infliximab treatment of rheumatoid arthritis patients, using PET, may predict clinical outcome.
评估英夫利昔单抗治疗 2 周后 18F-FDG 关节摄取变化与临床结果之间的相关性。
在治疗开始时和 2 周时进行扫描。使用标准化摄取值定量评估掌指关节和腕关节的摄取情况。
0-2 周时平均标准化摄取值的变化与 14 周和 22 周时的疾病活动评分（DAS）显著相关，并且对这些时间点的 DAS 预测具有显著贡献。0-2 周时急性期反应物的变化与后期 DAS 之间未发现显著相关性。
使用 PET 观察类风湿关节炎患者英夫利昔单抗治疗期间关节 18F-FDG 摄取的早期变化可能预测临床结果。
